For people with vitiligo and their caregivers
What this page helps you do
Understand what the current US label and pivotal trials establish before discussing whether this medicine is a realistic option.
- Your task
- Check the label boundary, evidence limits, material warnings, treatment burden, and coverage questions.
- The clinician boundary
- A prescriber must determine whether the diagnosis, health history, other treatments, warnings, and monitoring make this medicine appropriate.
Does FDA approval mean Opzelura fits my vitiligo?
Not automatically. In the United States, ruxolitinib cream is approved for nonsegmental vitiligo in adults and children ages 12 and older. The label also limits how much skin is treated. Your diagnosis must still match its pattern, age, extent, and other limits. Evidence
Why this matters
Ruxolitinib is a Janus kinase inhibitor, and Opzelura is the brand name. The FDA-approved prescribing information defines who was included in the indication, limitations of use, warnings, and other information your prescriber must apply.
How likely is it to help my patches?
In two phase 3 trials, more people reached defined color-return goals with ruxolitinib than with inactive cream. Many people in the trials did not reach those results. The trials cannot tell you how much your patches will change, where, or whether it will last. Evidence
Why this matters
The trials enrolled adolescents and adults with nonsegmental vitiligo under defined eligibility criteria and used standardized measures of repigmentation. Their randomized, controlled design supports a treatment effect in the population studied.
What should I understand about the boxed warnings?
The US label carries the FDA’s strongest safety alert, called a “boxed warning.” It covers serious risks reported with this drug class, called JAK inhibitors. Evidence
- Serious infections
- Cancer
- Major heart problems
- Blood clots
- Death
Why this matters
Some warning evidence comes from a different JAK inhibitor taken by mouth in another group. The label also calls for checks for non-melanoma skin cancer and limits sunlight and ultraviolet exposure. It advises against use with certain other immune-system treatments.
What if phototherapy is suggested too?
Ask the prescriber and light-therapy team to coordinate before you proceed. The current US ruxolitinib label includes ultraviolet-exposure precautions and does not establish when or how to add phototherapy. Do not create a combined plan yourself. Evidence
Why this matters
The label tells patients to limit sunlight and ultraviolet exposure and includes other medicine-specific warnings that the treating team must interpret.
What if insurance will not cover it or the cost is too high?
Coverage, insurer approval, pharmacy access, and your cost can decide whether the medicine is workable. They do not decide whether it is medically right for you. An insurer’s decision or eligibility for a maker program does not show whether the medicine will help you. Evidence
Why this matters
The medicine is prescription-only, and payer requirements differ by plan and can change. Ask the care team to separate the medical reason from the insurer’s rules. This keeps a coverage problem from being mistaken for a medical verdict.
Questions that can change the next decision
- For your prescriberDoes my diagnosis and health history fit the current US label, and which warnings matter most for me?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- For your prescriberWhat result would count as meaningful, and when would we review whether the burden and risks remain worthwhile?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- For your insurer or pharmacy benefit managerWhat current coverage rule, documentation, network pharmacy, and review route apply to this exact prescription?Saving keeps this on your device and needs JavaScript, which is off in this browser.
Evidence detail: current label and pivotal trials
Open this layer when you want the study and regulatory context behind the patient summary.
- Current US status
- The September 2025 FDA label includes topical treatment of nonsegmental vitiligo in adults and children 12 years and older, with additional indication limits and precautions for a prescriber to apply.
- What the pivotal evidence measured
- Two randomized, vehicle-controlled phase 3 trials enrolled 674 adolescents and adults with defined nonsegmental vitiligo and measured standardized facial and total-body repigmentation outcomes.
- What it did not establish
- The trials do not predict an individual result, establish superiority over every alternative, or answer every question for people outside the study criteria. The FDA label is authoritative for approved study labeling, but it is not independent efficacy evidence.
- Safety context
- The current label carries boxed warnings for serious infections, mortality, malignancy, major cardiovascular events, and thrombosis, plus product-specific precautions. A prescriber must interpret these for the individual.
Applicability check
Who was studied?
These fields show what the cited evidence reports about the people and body sites behind outcome or safety claims. “Not reported” means the reviewed source omitted the field; “Pending exact source review” means SteadySkin has not made that determination yet.
In two phase 3 trials, more people reached defined color-return goals with ruxolitinib than with inactive cream. Many people in the trials did not reach those results. The trials cannot tell you how much your patches will change, where, or whether it will last.
- Age range
- Pending exact source review
- Condition subtype
- Pending exact source review
- Severity or extent
- Pending exact source review
- Sample size
- Pending exact source review
- Geography and care setting
- Pending exact source review
- Skin tone or phototype
- Pending exact source review
- Race
- Pending exact source review
- Ethnicity
- Pending exact source review
- Body sites
- Pending exact source review
What that means for this page: This is explicitly gated as a group-level outcome claim, but exact population extraction is still pending. It cannot publish or support an individual prediction until that review is complete.
The US label carries the FDA’s strongest safety alert, called a “boxed warning.” It covers serious risks reported with this drug class, called JAK inhibitors. Serious infections Cancer Major heart problems Blood clots Death
- Age range
- Pending exact source review
- Condition subtype
- Pending exact source review
- Severity or extent
- Pending exact source review
- Sample size
- Pending exact source review
- Geography and care setting
- Pending exact source review
- Skin tone or phototype
- Pending exact source review
- Race
- Pending exact source review
- Ethnicity
- Pending exact source review
- Body sites
- Pending exact source review
What that means for this page: This is explicitly gated as a safety claim, but exact population extraction is still pending. It cannot publish or support an estimate of individual risk until that review is complete.
Evidence behind this page
Sources
Each evidence badge opens the source and its limits. The full list stays available here.
- U.S. Food and Drug AdministrationRegulatory / guideline · not independentIndependence not established
- Published
- 2025-09-18
- SteadySkin last checked
- 2026-08-06
What this source can and cannot tell you
What this source supports
Supports the defined US nonsegmental-vitiligo indication, limitations of use, boxed warnings, skin-cancer and ultraviolet precautions, and clinical-study labeling.
What it does not support
It does not guarantee benefit, establish suitability beyond the labeled population or authorize adding phototherapy.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.